Tech Company Financing Transactions

Escient Pharmaceuticals Funding Round

Abingworth, Forge Life Science Partners and New Enterprise Associates invested in a $120 million Series C venture round for Escient Pharmaceuticals. The round was announced on 11/28/2022.

Transaction Overview

Company Name
Escient Pharmaceuticals
Announced On
11/28/2022
Transaction Type
Venture Equity
Amount
$120,000,000
Round
Series C
Investors

Abingworth (Lead Investor)

Forge Life Science Partners (Lead Investor)

New Enterprise Associates (Lead Investor)

5AM Ventures (Andrew Schwab)

Sanofi Ventures

Proceeds Purpose
The financing will help the company advance its pipeline to clinical proof-of-concept in multiple indications.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
10578 Science Center Dr. 250
San Diego, CA 92121
USA
Phone
(858) 617-8220
Website
www.escientpharma.com
Email Address
[email protected]
Overview
Escient Pharmaceuticals. We are a privately held biotechnology company that is advancing first-in-class G Protein-Coupled Receptor (GPCR)-targeted drugs to address serious, unserved medical needs across a broad range of therapeutic indications.
Profile
Escient Pharmaceuticals LinkedIn Company Profile
Social Media
Escient Pharmaceuticals Company Twitter Account
Company News
Escient Pharmaceuticals News
Facebook
Escient Pharmaceuticals on Facebook
YouTube
Escient Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Alain Baron
  Alain Baron LinkedIn Profile  Alain Baron Twitter Account  Alain Baron News  Alain Baron on Facebook
Chief Scientific Officer
Marcus Boehm
  Marcus Boehm LinkedIn Profile  Marcus Boehm Twitter Account  Marcus Boehm News  Marcus Boehm on Facebook
Vice President
Richard Pittner
  Richard Pittner LinkedIn Profile  Richard Pittner Twitter Account  Richard Pittner News  Richard Pittner on Facebook
Vice President
Kristin Taylor
  Kristin Taylor LinkedIn Profile  Kristin Taylor Twitter Account  Kristin Taylor News  Kristin Taylor on Facebook
Vice President
Gregg Timony
  Gregg Timony LinkedIn Profile  Gregg Timony Twitter Account  Gregg Timony News  Gregg Timony on Facebook
VP - Bus. Development
William Hodder
  William Hodder LinkedIn Profile  William Hodder Twitter Account  William Hodder News  William Hodder on Facebook
VP - R & D
Esther Martinborough
  Esther Martinborough LinkedIn Profile  Esther Martinborough Twitter Account  Esther Martinborough News  Esther Martinborough on Facebook

 

 

Browse more venture capital transactions:

Prev: 11/28/2022: Strand Therapeutics venture capital transaction
Next: 11/29/2022: Roboto Games venture capital transaction

 

Share this article

 

About Our Venture Capital Transactions Database

We report on every notable VC transaction. VC investment data records reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.